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Abstract
Background: Previous studies have shown that chromobox 4 (CBX4) expression may involve 
in the progression of liver cancer, however, it is unclear whether it affects the prognosis of 
hepatocellular carcinoma (HCC) related to aflatoxin B1 (AFB1).
Methods: A retrospective study was conducted in the high AFB1 exposure areas and a total 
of 428 patients with HCC were included in the final survival analyses. AFB1 exposure levels 
and CBX4 expression in the tumor tissues were tested using enzyme-linked immunosorbent 
assay and immunohistochemistry, respectively. The effects of AFB1 and CBX4 on HCC out-
come were elucidated by Kaplan–Meier survival method and Cox regression model.
Results: We found that the levels of AFB1 exposure and CBX4 expression in tumor tissues 
were significantly associated with some clinicopathological features such as microvessel 
density and tumor stage. Furthermore, both AFB1 and CBX4 significantly modified overall 
survival and tumor reoccurrence-free survival status of HCC. Additionally, some evidence 
of CBX4-AFB1 interaction affecting HCC prognosis was observed, with an interactive value 
of 1.98 for overall survival and 1.94 for tumor reoccurrence-free survival, respectively.
Conclusion: These results suggest that CBX4 expression might be a useful marker for AFB1-
related HCC prognosis.
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1. Introduction
Aflatoxin B1 (AFB1) is a type of secondary metabolite of Aspergillus parasiticus and Aspergillus 
flavus, and frequently contaminates a series of staple foods, such as ground nuts, and maize 
[1–3]. Once this type foods contaminated by AFB1 entered into human bodies, it is metabolized 
into its epoxides consisting of AFB1–8,9-exo-epoxide (AFBEX) and AFB1–8,9-endo-epoxide 
(AFBEN) by cytochrome P450 (CYP) metabolic system [3]. These products of AFB1, especially 
AFBEX, are characterized by high reaction, genic toxicity, and carcinogenicity [3]. Evidence 
from molecular epidemiology and animal models has shown that AFB1 is an important car-
cinogen inducing hepatocellular carcinoma (HCC) [4–10]. Mechanically, the carcinogenesis of 
AFB1-related HCC mainly involves in the formation of DNA damage (including AFB1-DNA 
adducts, DNA single-strand breaks, DNA double-strands breaks, and gene mutations), the 
inactivation of such tumor suppressor gene as TP53, and the activation of cancer genes such as 
Ras [3, 11–15]. Although some advance in the pathogenesis of AFB1-related HCC has obtained 
in the past decades [16–18], it is still far for us to elucidate more detailed mechanisms.
The chromobox 4 (Cbx4) (GenBank accession NO. 8535) consists of six exons and spans about 
6.26 kb on chromosome 17q25.3. This gene encodes a 560-amino acid protein which is the impor-
tant component of polycomb repressive complex 1 (PRC1) [19–22]. Functionally, CBX4 involves 
in PRC1-regulated transcription repression and post-translation modification [19–22]. Recently, 
increasing evidence has exhibited that the dysregulation of this gene may affect the carcinogenic 
process of some tumors such as HCC, colorectal cancer, breast cancer, and so on, and may be a 
significant prognostic biomarker [19, 21, 23–29]. However, it is not clear whether CBX4 modify 
the prognosis of AFB1-related HCC. Here, we conducted a hospital-based retrospective study to 
investigate whether the CBX4 expression in the cancerous tissues is associated with the outcome 
of HCC related to AFB1 expression in the Guangxi Region, a high AFB1 exposure area.
2. Materials and methods
2.1. Study population
Between January 2009 and December 2012, 428 consecutive patients with histopathologically 
confirmed hepatocarcinoma were recruited at the Divisions of Oncology and Pathology, 
the affiliated Hospitals of Guangxi Medical University and Youjiang Medical University for 
Nationalities. During the recruitment phase, only 5 cases refused to participate in the study 
(response rate 98.8%). All cases were from high AFB1 exposure areas, including Nanning, Bose, 
Tiandong, and Tianyang. After informed consent was obtained, surgically removed tumor sam-
ples were collected to analyze the amounts of AFB1-DNA adducts and CBX4 protein in the can-
cerous tissues. Additionally, all corresponding clinicopathological and survival following-up 
data were also collected in the hospitals as previously described methods [30-32]. In this study, 
the status of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection was evaluated using 
serum hepatitis B surface antigen (HBsAg) and anti-HCV, respectively; whereas the grade and 
stage of tumor was elucidated using the Edmondson and Steiner (ES) grading system and the 
Barcelona Clinic Liver Cancer (BCLC) staging system, respectively. For survival analyses, the 
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last follow-up day was set on December 31, 2017. The study protocol was carried out according 
to the approved guidelines by the Institutional Ethics Committee from the Affiliated Hospitals 
of Youjiang Medical University for Nationalities and Guangxi Medical University.
2.2. Microvessel density (MVD) assay
MVD in the cancerous tissues was assessed using the immunohistochemistry staining of 
CD31 as our previously descripted [30]. In this study, positive status of MVD was defined as 
microvessel counts more than 50 per ×200 magnifications.
2.3. AFB1 exposure data
AFB1 exposure levels were evaluated using the amounts of AFB1-DNA adducts in the cancer-
ous tissues as our previously descripted [31, 32]. The amounts of AFB1-DNA adduct were 
tested using the competitive enzyme-linked immunosorbent assay. In this study, a value than 
less 1.00 μmol/mol DNA was considered as negative status for AFB1 exposure.
2.4. CBX4 expression assays
The level of CBX4 protein expression in cancerous tissues was elucidated using our pre-
viously published immunohistochemistry method [33, 34]. Briefly, the amounts of CBX4 
protein were tested using anti-CBX4 antibody and calculated using immunoreactive score 
system (IRS). In the present study, positive CBX4 protein in cancerous tissues was define 
as IRS > 4.
2.5. Statistical analysis
Logistic regression model with enter method for variables (including all known clinicopatho-
logical features) was used for statistical comparison between groups. The odd ratios (ODs) 
and corresponding 95% confidence intervals (CIs) were calculated in this model for evaluat-
ing the association between clinicopathological features of HCCs and either AFB1 exposure 
or CBX4 expression. Kaplan–Meier survival method with log-rank test was used for statistical 
comparisons between different levels of AFB1 expression and CBX4 expression. Multivariate 
Cox regression model (with retread method based on likelihood ratio test) analyses were 
performed to calculate the risk strength of independent variates and prognostic values. In this 
study, all analyses were finished using the SPSS soft version 18.0 (SPSS Inc. Chicago, IL), and 
a P-value less than 0.05 was defined as statistical significance.
3. Results
3.1. The clinicopathological and survival features of HCC cases
Table 1 gave the clinicopathological characteristics of all cases, and a total of 428 patients 
with HCC were included in the final analyses. All cases were followed-up more than 
5 years to obtain median survival time. During the follow-up period, 261 patients with 
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Variables n %
Total 428 100.0
Age, years
Mean ± SE 47.9 ± 10.1 —
Range 30–75 —
Sex
Man 290 68.9
Female 138 32.8
Ethnicity
Han 229 54.4
Zhuang 199 47.3
HBV status
HBsAg (−) 113 26.8
HBsAg (+) 315 74.8
HCV status
anti-HCV (−) 378 89.8
anti-HCV (+) 50 11.9
Smoking status
No 315 74.8
Yes 113 26.8
Drinking status
No 304 72.2
Yes 124 29.5
AFP (ng/mL)
≤ 20 154 36.6
> 20 274 65.1
Liver cirrhosis
No 104 24.7
Yes 324 77.0
BCLC stage
A 167 39.7
B 121 28.7
C 140 33.3
Tumor size
≤ 3 cm 211 50.1
> 3 cm 217 51.5
MVD
Negative 192 45.6
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HCC featured cancer recurrences with 30.00 (22.20–37.80) months of median recurrence-
free survival time (MRT), and 270 died with 45.00 (38.98–51.02) months of median overall 
survival time (MST).
3.2. The effects of AFB1 exposure on the clinicopathological features and the 
prognosis of HCC cases
In this study, the status of AFB1 exposure was elucidated using the amount of AFB1-DNA 
adducts in the cancerous tissues. Results from competitive ELISA exhibited the patients 
with HCC featured a 2.82 ± 1.60 μmol/mol DNA of AFB1 exposure level. To investigate the 
effects of AFB1 exposure on the clinicopathological features of HCC cases, we defined the 
amount of AFB1-DNA adducts ≤1.00 μmol/mol DNA as negative AFB1 exposure accord-
ing to our previous published results [31, 32]. Our results showed that these patients with 
positive AFB1 status (AFB1-DNA adducts: > 1.00 μmol/mol DNA) had higher BCLC stage 
(adjusted OR = 2.09 and adjusted 95% CI = 1.04–4.24), bigger tumor size (adjusted OR = 69.06 
and adjusted 95% CI = 33.62–141.86), and higher MVD (adjusted OR = 2.56 and adjusted 
95% CI = 1.36–4.81) compared with those without positive AFB1 status (OR = 1) (Table 2). 
Additionally, we also found that the levels of AFB1 exposure were significantly associated 
with the age of patients with hepatocarcinoma (adjusted OR = 1.80, adjusted 95% CI = 1.22–
2.66, and P = 3.07×10−3). However, AFB1 exposure was not correlated with other clinicopatho-
logical features of HCCs (Table 2).
Next, we investigated the effects of AFB1 exposure on the HCC prognosis using Kaplan–
Meier survival model (Figure 1A). Results exhibited that HCC cases with negative AFB1 
status (AFB1-DNA adducts: ≤ 1.00 μmol/mol DNA) featured longer median overall survival 
time (MST) [69.00 (55.41–82.59) months] and median tumor reoccurrence-free survival time 
(MRT) [70.00 (44.93–95.07) months] compared with those with positive AFB1 status [20.00 
(13.04–26.96) months for MST and 13.00 (9.54–16.46) months for MRT, respectively].
3.3. The effects of CBX4 expression on the clinicopathological features and the 
prognosis of HCC cases
In the present, the levels of CBX4 protein in the cancerous tissues were amounted using immu-
nohistochemistry technique with IRS counting system and the median IRS value was 5.58 for 
Variables n %
Positive 236 56.1
ES grade
Low 226 53.7
High 202 48.0
Abbreviations: AFP, α-fetoprotein; BCLC, the Barcelona Clinic Liver Cancer staging system; ES, Edmondson and Steiner 
grading system; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; MVD, microvessel 
density.
Table 1. The clinic-pathological features of cases with hepatocellular carcinoma.
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AFB1 (−) AFB1 (+)
Variables n % n % OR (95% CI) P
trend
Total 244 100.0 184 100.0 — —
Age (years)
≤ 48 148 60.7 86 46.7 Reference
> 48 96 39.3 98 53.3 1.80 (1.22–2.66) 3.07 × 10−3
Sex
Man 160 65.6 130 70.7 Reference
Female 84 34.4 54 29.3 1.13 (0.59–2.13) 0.72
Ethnicity
Han 124 50.8 105 57.1 Reference
Zhuang 120 49.2 79 42.9 0.99 (0.55–1.78) 0.98
HBsAg
Negative 65 26.6 48 26.1 Reference
Positive 179 73.4 136 73.9 1.19 (0.60–2.34) 0.61
anti-HCV
Negative 217 88.9 161 87.5 Reference
Positive 27 11.1 23 12.5 1.25 (0.51–3.09) 0.62
Smoking status
No 181 74.2 134 72.8 Reference
Yes 63 25.8 50 27.2 0.48 (0.12–1.85) 0.28
Drinking status
No 174 71.3 130 70.7 Reference
Yes 70 28.7 54 29.3 2.61 (0.69–9.89) 0.27
AFP (ng/mL)
≤ 20 82 33.6 72 39.1 Reference
> 20 162 66.4 112 60.9 1.00 (0.55–1.82) 0.99
Liver cirrhosis
No 58 23.8 46 25.0 Reference
Yes 186 76.2 138 75.0 0.84 (0.42–1.69) 0.63
BCLC stage
A 113 46.3 54 29.3 Reference
B 69 28.3 52 28.3 1.27 (0.61–2.61) 0.52
C 62 25.4 78 42.4 2.09 (1.04–4.24) 0.04
Tumor size
≤ 3 cm 197 80.7 14 7.6 Reference
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all cases with hepatocarcinoma. According to the results from the CBX4 expression in cancer-
ous tissues based on a large sample, IRS > 4 was regarded as positive CBX4 status. Table 3 
summarized the association between CBX4 expression in the cancerous tissues and the clini-
copathological features, and results from multivariable logistic regression models proved that 
the levels of CBX4 expression were significantly related to increasing risk of liver cirrhosis 
(OR = 1.75 and 95% CI = 1.07–2.88), higher tumor stage (OR = 2.02 and 95% CI = 1.23–3.33), and 
increasing MVD (OR = 2.66 and 95% CI = 1.74–4.07). However, CBX4 expression levels did not 
affect other clinicopathological features such as tumor size, grade, AFP, and so on.
Results from Kaplan–Meier survival analyses further displayed that HCC patients with 
positive status of CBX4 protein expression had short MST [22.00 (18.00–26.00) months] and 
MRT [16.00 (10.88–21.12) months] compared with those with negative-status CBX4 protein 
[69.00 (52.75–85.25) months for MST and 48.00 (23.69–72.31) months for MRT, respectively] 
(Figure 1B). Taken together, CBX4 expression in the cancerous might be an important bio-
marker for HCC prognosis.
3.4. The joint effects of AFB1 exposure and CBX4 expression on HCC prognosis
Given that both AFB1 exposure and CBX4 expression modified HCC outcome, we questioned 
whether CBX4 expression interacted with AFB1 expression, and whether this interaction 
affected the prognosis of hepatocarcinoma. First, we analyzed the joint effects of AFB1 expo-
sure and CBX4 expression on the prognosis of patients with HCC using Kaplan–Meier sur-
vival model (Figure 2). In this model, the combination of AFB1 exposure and CBX4 expression 
was divided into four groups: cases with negative-AFB1 and negative-CBX4 status (AC-1), 
cases with negative-AFB1 and positive-CBX4 status (AC-2), cases with positive-AFB1 and 
negative-CBX4 status (AC-3), and cases with positive-AFB1 and positive-CBX4 status (AC-4). 
We found MST and MRT gradually decreased from AC-1 to AC-4 (89.00–11.00 months for 
MST and more than 125.00–7.00 months for MRT, respectively) (Figure 2A and B).
AFB1 (−) AFB1 (+)
Variables n % n % OR (95% CI) P
trend
> 3 cm 47 19.3 170 92.4 69.06 (33.62–141.86) 9.36 × 10−31
MVD
Negative 118 48.4 74 40.2 Reference
Positive 126 51.6 110 59.8 2.56 (1.36–4.81) 3.46 × 10−3
ES grade
Low 129 52.9 97 52.7 Reference
High 115 47.1 87 47.3 1.52 (0.64–2.07) 0.64
Abbreviations: AFP, α-fetoprotein; BCLC, the Barcelona Clinic Liver Cancer staging system; ES, Edmondson and Steiner 
grading system; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; MVD, microvessel 
density.
Table 2. The association between AFB1 exposure and clinic-pathological features of hepatocellular carcinoma cases.
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We next finished multivariable Cox regression analyses based on the retread method with 
likelihood ratio test (including significant variables and all kinds of possible interactive vari-
ables) (Table 4), and found both AFB1 exposure and CBX4 expression in the cancerous tissues 
were independent prognostic factors. Furthermore, we also observed that AFB1 exposure sig-
nificantly and multiplicatively interacted with CBX4 protein expression (interactive values, 
1.98 for overall survival and 1.94 for tumor reoccurrence-free survival, respectively).
Figure 1. Both AFB1 exposure and CBX4 expression significantly correlating with hepatocellular carcinoma. AFB1 
exposure levels were elucidated using the amount of AFB1-DNA adducts in the cancerous tissues. The CBX4 expression 
in cancerous tissues from 428 patients with hepatocellular carcinoma was tested using immunohistochemistry technique 
based on immunoreactive score system (IRS). To analyze, the levels of CBX4 expression were divided into two groups: 
Negative group (IRS ≤ 4) and positive group (IRS > 4). AFB1 exposure (A) and CBX4 expression (B) are associated 
with overall survival (left) and tumor recurrence-free survival (right) of hepatocellular carcinoma. Cumulative hazard 
function was plotted by Kaplan–Meier’s methodology, and P value was calculated with two-sided log-rank tests. 
Abbreviations: CBX4, chromobox 4; MST, median overall survival time; MRT, median tumor recurrence-free survival 
time; CI, confidence interval.
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CBX4 (−) CBX4 (+)
Variables n % n % OR (95% CI) P
trend
Total 233 100.0 195 100.0 — —
Age (years)
≤ 48 136 58.4 98 50.3 Reference
> 48 97 41.6 97 49.7 1.35 (0.89–2.05) 0.67
Sex
Man 160 68.7 130 66.7 Reference
Female 73 31.3 65 33.3 1.14 (0.73–1.78) 0.57
Ethnicity
Han 121 51.9 108 55.4 Reference
Zhuang 112 48.1 87 44.6 0.96 (0.63–1.46) 0.85
HBsAg
Negative 65 27.9 48 24.6 Reference
Positive 168 72.1 148 75.9 1.17 (0.73–1.89) 0.51
anti-HCV
Negative 209 89.7 169 86.7 Reference
Positive 24 10.3 26 13.3 1.43 (0.74–2.75) 0.29
Smoking status
No 176 75.5 139 71.3 Reference
Yes 57 24.5 56 28.7 1.04 (0.37–2.93) 0.94
Drinking status
No 172 73.8 132 67.7 Reference
Yes 61 26.2 63 32.3 1.40 (0.51–3.83) 0.51
AFP (ng/mL)
≤ 20 84 36.1 70 35.9 Reference
> 20 149 63.9 125 64.1 1.11 (0.72–1.70) 0.64
Liver cirrhosis
No 69 29.6 35 17.9 Reference
Yes 164 70.4 160 82.1 1.75 (1.07–2.88) 0.03
BCLC stage
A 112 48.1 55 28.2 Reference
B 58 24.9 63 32.3 1.94 (1.16–3.24) 0.01
C 63 27.0 77 39.5 2.02 (1.23–3.33) 5.79×10−3
Tumor size
≤ 3 cm 121 51.9 90 46.2 Reference
> 3 cm 112 48.1 105 53.8 1.24 (0.81–1.88) 0.33
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4. Discussion
In Guangxi Zhuang Autonomous Region, HCC is the most malignant disease. In the past 
decades, the annual incidence and death rate (AIR and ADR) of hepatocarcinoma in this area 
has been reported to remarkably increase (up to about 100–200 per 10,000 for AIR about 50 
per 10,000 for ADR) [1]. Lots of epidemiological studies have shown that AFB1 exposure is 
CBX4 (−) CBX4 (+)
MVD
Negative 131 56.2 61 31.3 Reference
Positive 102 43.8 134 68.7 2.66 (1.74–4.07) 6.65×10−6
ES grade
Low 132 56.7 94 48.2 Reference
High 101 43.3 101 51.8 1.39 (0.92–2.11) 0.12
Abbreviations: AFP, α-fetoprotein; BCLC, the Barcelona Clinic Liver Cancer staging system; CBX4, chromobox 4; ES, 
Edmondson and Steiner grading system; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C 
virus; MVD, microvessel density.
Table 3. The correlation between CBX4 expression and clinical pathological features of hepatocellular carcinoma.
Figure 2. Survival analysis of CBX4 expression binding AFB1 exposure levels. The combination of CBX4 expression 
and AFB1 exposure was divided into 4 strata: Cases with negative-AFB1 and negative-CBX4 status (AC-1), cases with 
negative-AFB1 and positive-CBX4 status (AC-2), cases with positive-AFB1 and negative-CBX4 status (AC-3), and cases 
with positive-AFB1 and positive-CBX4 status (AC-4). This kind of joint analyses showed that interactive effects on 
the overall survival (A) and tumor recurrence-free survival (B) of patients with hepatocarcinoma. Cumulative hazard 
function was plotted by Kaplan–Meier’s methodology, and P value was calculated with two-sided log-rank tests. 
Abbreviations: CBX4, chromobox 4; MST, median overall survival time; MRT, median tumor recurrence-free survival 
time; CI, confidence interval.
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the most important cause for this high AIR and ADR [1]. AFB1 is a known I-type chemical 
carcinogen produced by Aspergillus parasiticus and Aspergillus flavus, and has been proved 
to involve in the carcinogenesis and progression of HCC [4–10]. This carcinogenicity of 
AFB1 mainly results from its metabolic product binding to DNA and inducing DNA dam-
age. Among DNA damage types induced by AFB1, AFB1-DNA adducts are very important, 
because of its non-enzymatic, time-dependent, and apparent persistent characteristics in the 
genomic DNA strands [3, 35]. Our previous studies have exhibited that AFB1-DNA adducts, 
especially from liver tissues, are highly associated not only with increasing HCC risk, but 
with the poor prognosis of HCC [2, 31, 36–39]. Here, our data displayed that increasing levels 
of AFB1 exposure significantly correlated with higher tumor stage, increasing tumor size, and 
higher MVD; furthermore, AFB1 was also poor prognostic marker for HCC. Taken together, 
these data suggest that AFB1 may involve in the startup and progression of HCC.
Because several previous studies have exhibited that CBX4 can progress tumorigenesis via 
several signal pathways, including CBX4/HIF-1α/VEGF pathway [20, 25, 26, 34], CBX4/
HDAC3/Runx2 pathway [21], CBX4/P63 pathway [22], CBX4/miR-195 pathway [40], CBX4/
CtIP pathway [41], and CBX4/P53 pathway [42, 43], here we investigated the effects of CXB4 
expression on HCC outcome. We not only found that increasing CBX4 expression in the 
cancerous tissues is a poor prognostic biomarker for HCC, but this increasing expression is 
associated with clinicopathological features such as tumor size, tumor stage, and angiogen-
esis. Supporting our findings, several recent reports further prove that CBX4 can govern the 
several biofunctions of HCC, including proliferation, invasion and metastasis, angiogenesis, 
and metastasis [20, 25, 26, 34, 40, 44].
Noticeably, some evidence of the joint effects of CBX4 and AFB1 on HCC outcome was 
observed in the prognostic analyses based on the gene-environmental joint effects. Our 
results showed that CBX4 expression significantly and multiplicatively interacted with AFB1 
exposure levels, and that this multiplicative interaction remarkably increased the death risk 
and tumor reoccurrence risk of patients with HCC. Recently, two studies from high AFB1 
exposure areas have also reported that the dysregulation of CBX4 in the cancerous tissues 
from patients with hepatocarcinoma increases MVD, promotes angiogenesis, and increases 
sensitivity of HCC cells on anti-cancer drugs [33, 34]. Altogether, these results are indicative 
of the angiogenesis induced by CBX4 involving in the progression of AFB1-related HCC.
OS RFS
Variables HR (95%CI) Ptrend HR (95%CI) Ptrend
AFB1 2.09 (1.64–2.65) 2.34 × 10−9 2.29 (1.79–2.93) 3.82 × 10−11
CBX4 1.76 (1.38–2.24) 4.66 × 10−6 1.80 (1.41–2.30) 3.12 × 10−6
AFB1 × CBX4 1.98 (1.61–2.59) 9.43 × 10−7 1.94 (1.58–2.54) 8.17 × 10−5
HR and corresponding 95% CI was calculated using multivariable Cox regression model (with retread method based 
on likelihood ratio test). Abbreviations: AFB1, aflatoxin B1; CBX4, chromobox 4; OS, overall survival; RFS, tumor 
reoccurrence-free survival; HR, hazard ratio; CI, confidence interval.
Table 4. The effects of AFB1 and CBX4 expression on the prognosis of cases with hepatocellular carcinoma.
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In summary, our present study proposes that CBX4 expression in the cancerous tissues can 
act as a valuable biomarker for AFB1-related HCC. However, several limitations confine the 
value of this study. First, because of the hospital-based retrospective design, selective bias 
may take place. Second, because liver damage itself affects AFB1 metabolite and may increase 
the amount of AFB1-DNA adducts, the prognostic and interactive values of AFB1 and CBX4 
may be underestimated. Finally, we did not do functional and mechanical analyses. Therefore, 
detailed functional analyses deserve further evaluation on the basis of the foresighted design 
and the combination of AFB1 and CBX4.
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